Fares, M.-B. | bioRxiv Science

bioRxiv2022

Comparative analysis of total alpha-synuclein (αSYN) immunoassays reveals that they do not capture the diversity of modified αSYN proteoforms

BackgroundThe development of therapeutics for Parkinsons disease (PD) requires the establishment of biomarker assays to enable stratifying patients, monitoring disease progression and assessing target engagement. Attempts to develop diagnostic assays based on detecting levels of the -synuclein (SYN) protein, a central player in the pathogenesis of PD, have yielded inconsistent results. ObjectiveTo determine whether the three commercial kits that have been extensively used for total SYN quantification in human biological fluids (from Euroimmun, MSD, and Biolegend) are capable of capturing the diversity and complexity of relevant SYN proteoforms. MethodsWe investigated and compared the ability of the different assays to detect the diversity of SYN proteoform using a library of SYN proteins that compromise the majority of disease-relevant SYN variants and post-translational modification. ResultsOur findings showed that none of the three tested immunoassays accurately capture the totality of relevant SYN species and are unable to recognize most disease-associated C-terminally truncated variants of SYN. Moreover, several N-terminal truncations and phosphorylation/nitration differentially modify the level of SYN detection and recovery by different immunoassays, and a CSF matrix effect was observed for most of the SYN proteoforms analyzed by the three immunoassays. ConclusionsOur results showed that these immunoassays do not capture the totality of the relevant SYN species and therefore may not be appropriate tools to provide an accurate measure of total SYN levels in samples containing modified forms of the protein. This highlights the need for next-generation SYN immunoassays that capture the diversity of SYN proteoforms.

neuroscience↗

bioRxiv2018

N-terminal phosphorylation of Huntingtin: A molecular switch for regulating Htt aggregation, helical conformation, internalization and nuclear targeting.

Phosphorylation of exon1 of the Huntingtin protein (Httex1) has been shown to play important roles in regulating the structure, toxicity and cellular properties of N-terminal fragments and the full-length Huntingtin protein. Here, we investigated and compared the effect of bona fide phosphorylation at S13 and/or S16 on the structure, aggregation, membrane binding, and subcellular properties of mutant Httex1-Q18A. We show that serine phosphorylation at either S13 or S16 strongly disrupts the amphipathic -helix of the N-terminus, inhibits the aggregation of mutant Httex1 and prompts the internalization and nuclear targeting of Httex1 preformed aggregates. In synthetic peptides phosphorylation at S13 and/or S16 strongly disrupted the amphipathic -helix of the N-terminal 17 residues (Nt17) of Httex1 and Nt17 membrane binding. Our studies on peptides bearing a different combination of phosphorylation sites within Nt17 revealed a novel phosphorylation-dependent switch for regulating the structure of Httex1 involving crosstalk between phosphorylation at T3 and S13 or S16. Together, our results provide novel insights into the role of phosphorylation in regulating Httex1 structure and function in health and disease and underscore the critical importance of identifying enzymes responsible for regulating Htt phosphorylation and their potential as therapeutic targets for the treatment of Huntingtons disease.

neuroscience↗